stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
18.23
1.06
−5.50%
Follow MMED
Alert me
| Jul '26 | Apr '26 | Jan '26 | Jul '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 |
+3 more quarters Free account |
P/S ratio |
1.67 | — | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(103.51) | — | (173.13) | (173.13) | |
P/B ratio |
1.40 | — | 1.35 | 1.35 | |
Price to Tangible BV |
4.01 | — | 4.27 | 4.27 | |
EV/Sales |
1.60 | — | 0.00 | 0.00 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(36.31) | — | (166.59) | (166.59) | |
EV/FCF |
(10.76) | — | (10.58) | (10.58) | |
Quick Ratio |
0.49 | 0.71 | 0.95 | — | |
Current Ratio |
1.81 | 1.92 | 1.59 | — | |
Net Debt/EBITDA |
(4.60) | 0.00 | 0.10 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.29 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.00 | — | 0.23 | 7.42 | |
Capex/Depreciation |
(1.00) | — | (1.43) | (1.36) | |
Research and Development Expense of Revenue |
13.64% | — | 14.43% | 17.29% | |
Selling, General and Administrative Expense of Revenue |
37.01% | — | 39.11% | 39.14% | |
Intangible Assets out of Total Assets |
0.50 | 0.51 | 0.55 | 0.00 | |
Share Based Compensation of Revenue |
1.19% | — | 4.81% | 1.24% | |
Graham Net Nets |
0.06 | — | 0.05 | 0.05 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(3.27%) | — | (3.27%) | (3.27%) | |
Free Cash Flow Yield |
(8.91%) | — | (9.43%) | (9.43%) | |
Revenue per Share |
3.00 | — | 3.12 | 2.86 | |
Operating CF per Share |
(0.17) | — | (0.11) | (0.56) | |
Capex per Share |
(0.15) | — | (0.66) | (0.21) | |
Free Cash Flow per Share |
(0.32) | — | (0.77) | (0.77) | |
Cash per Share |
0.74 | 0.00 | 0.04 | 0.00 | |
Shareholders Equity per Share |
12.88 | 0.00 | 13.69 | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
12.88 | 0.00 | 13.69 | 0.00 | |
Free Cash Flow |
(90.00) | — | (194.00) | (194.00) | |
Working Capital |
635.00 | 646.00 | 412.00 | — | |
Capital Expenditures |
(41.00) | — | (167.00) | (53.00) | |
Net Current Asset Value |
319.00 | 329.00 | 227.00 | 0.00 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.05 | — | 0.21 | 0.07 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
2,359.00 | 2,315.00 | 2,171.50 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026